---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-001806"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:45:29.864095+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexaria receives positive FDA pre-IND response for DehydraTECH-CBD hypertension program

## Summary
- FDA agreed to 505(b)(2) NDA pathway, typically enabling faster commercial approval.
- Proposed Phase Ib protocol for 100 hypertension patients received favorably by FDA.
- FDA confirmed no additional non-clinical studies required before IND initiation.
- Lexaria can now work towards opening IND and full registration of DehydraTECH-CBD.

## SEC filing metadata
- accession: 0001640334-22-001806
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001806/0001640334-22-001806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033422001806/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-001806
- JSON: https://secwatch.observer/filing/0001640334-22-001806.json
- Plain text: https://secwatch.observer/filing/0001640334-22-001806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.